Telix Completes Phase 3 Trial Enrollment and Aligns With FDA on Drug Approval Path

Telix Pharmaceuticals has finished enrolling patients in its Phase 3 BiPASS clinical study and has established a regulatory pathway with the FDA for a New Drug Application. The milestone marks a significant step toward potential commercial approval for the investigational therapy.